#USA #San Francisco #Stämm #Bioreactor #Antibody Production

Revolutionizing Antibody Production

Stämm, a pioneer in biofabrication solutions, is setting new benchmarks in the production of monoclonal antibodies through its innovative continuous bioreactor. Recent pilot studies carried out in Germany, Switzerland, and Argentina have showcased unprecedented results, highlighting substantial increases in productivity and efficiency. With a staggering increase of up to 30 times in antibody production, Stämm is addressing the growing demand for effective healthcare solutions in a competitive landscape.

The Breakthrough Technology

At the core of Stämm's success is its continuous laminar flow bioreactor, known as the Bioprocessor. Unlike traditional batch systems, this advanced bioprocessor features a unique bubble-free operation that allows for enhanced scalability and incredible cost efficiencies. Current data indicates that volumetric productivity has already experienced a 15-fold increase, with projections suggesting that it may surge to a 50-fold increase within the next year.

One of the key advantages of Stämm's bioreactor is its ability to significantly improve cell density and specific productivity, which can increase by as much as four times. This is particularly beneficial for the biopharmaceutical sector that seeks efficient production methods without compromising the quality of final products.

Meeting an Increasing Demand

As the healthcare industry grapples with rising demands for therapies, particularly for chronic diseases and complex conditions like oncology, inflammation, and immunology, Stämm is at the forefront of enabling the commercialization of biosimilars and other biological products. The biomanufacturing process for cell and gene therapies is significantly enhanced through the Bioprocessor’s high surface-to-volume ratio and low shear stress, augmenting automation capabilities as well.

The closed-system design of Stämm utilizes 3D-printed single-use cartridges, achieving optimal scalability and profitability. With successful pilot implementations completed in under three months, the bioreactor is primed for global distribution and is poised to serve underserved markets efficiently.

A Vision for Future Innovations

Stämm's significant increases in productivity stem from its ability to maintain a stable and stress-free environment that guarantees consistent optimal conditions, including high gas exchange rates. As the pharmaceutical industry faces an impending intellectual property cliff, Stämm is ideally positioned to facilitate access to scalable biomanufacturing solutions. Their proactive approach is setting the stage for next-generation drug production and inspiring innovation in the global biological product manufacturing space.

About Stämm

Established in 2016, Stämm aims to redefine the landscape of biofabrication by developing fully automated bioprocessors designed to revolutionize the production of biological products. Their bubble-free continuous manufacturing platform, featuring a pioneering 3D-printed bioreactor, promises enhanced yields while minimizing costs and environmental impact. With an emphasis on energy efficiency, Stämm not only provides scalable and economical solutions for biological product manufacturing but also decentralizes bioprocessing. This empowers their partners to focus squarely on groundbreaking discoveries that change lives. For more information, visit Stämm's website.